{"protocolSection":{"identificationModule":{"nctId":"NCT01605825","orgStudyIdInfo":{"id":"DALF-PS-1003"},"organization":{"fullName":"Acorda Therapeutics","class":"INDUSTRY"},"briefTitle":"A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke","officialTitle":"A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2015-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-05"},"primaryCompletionDateStruct":{"date":"2013-02","type":"ACTUAL"},"completionDateStruct":{"date":"2013-03","type":"ACTUAL"},"studyFirstSubmitDate":"2012-05-21","studyFirstSubmitQcDate":"2012-05-23","studyFirstPostDateStruct":{"date":"2012-05-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-28","resultsFirstSubmitQcDate":"2014-01-28","resultsFirstPostDateStruct":{"date":"2014-03-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-12-18","lastUpdatePostDateStruct":{"date":"2016-01-22","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Acorda Therapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","CARE_PROVIDER"]}},"enrollmentInfo":{"count":83,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"placebo/dalfampridine-ER","type":"PLACEBO_COMPARATOR","description":"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:\n\nPeriod 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36","interventionNames":["Drug: placebo/dalfampridine-ER"]},{"label":"dalfampridine-ER/placebo","type":"PLACEBO_COMPARATOR","description":"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:\n\nPeriod 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36","interventionNames":["Drug: dalfampridine-ER/placebo"]}],"interventions":[{"type":"DRUG","name":"placebo/dalfampridine-ER","description":"Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart","armGroupLabels":["placebo/dalfampridine-ER"]},{"type":"DRUG","name":"dalfampridine-ER/placebo","description":"Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart","armGroupLabels":["dalfampridine-ER/placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs)","description":"A TEAE is defined as any adverse event with date of onset (or worsening) on or after the start-date of double-blind treatment through 7 days after the last dose of double-blind treatment.\n\nThe severity categories of mild, moderate or severe, are defined below:\n\n* Mild is defined as causing no limitation of usual activities\n* Moderate is defined as causing some limitation of usual activities\n* Severe is defined as causing inability to carry out usual activities","timeFrame":"up to 36 days"}],"otherOutcomes":[{"measure":"Walking Speed Measured by the Timed 25 Foot Walk Test (T25FW)","timeFrame":"Screening visit, Days 1, 8, 15, 22, 29 and 36"},{"measure":"Motor and Sensory Function as Measured by the Fugl-Meyer Assessment (FMA)","timeFrame":"Screening visit, Days 1, 8, 15, 22, 29, and 36"},{"measure":"Manual Dexterity as Measured by the Box and Block Test","timeFrame":"Days 1, 8, 15, 22, 29, and 36"},{"measure":"Assistance Required to Perform Activities of Daily Living (ADL) by the Functional Independence Measure (FIM) Scale","timeFrame":"Days 1, 8, 15, 22, 29, and 36"},{"measure":"Subject Global Impression (SGI) Scale","timeFrame":"Days 8, 15, 22, 29 and 36"},{"measure":"Clinician Global Impression (CGI) Scale","timeFrame":"Days 8, 15, 22, 29 and 36"},{"measure":"Hand Strength as Measured by the Grip Test and Pinch Tests","timeFrame":"Days 1, 8, 15, 22, 29, and 36"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of a stable sensorimotor deficit due to an ischemic stroke, as confirmed by the Investigator with supportive prior imaging findings (MRI/ CT scan)\n* ≥ 6 months post-stroke\n* Have a body mass index (BMI) ranging between 18.0 - 35.0 kg/m,2 inclusive\n* Stable concomitant medication therapy regimen within 4 weeks of screening visit\n\nExclusion Criteria:\n\n* History of seizures, except simple febrile seizures\n* Moderate or severe renal impairment as defined by a calculated creatinine clearance of ≤ 50 mL/minute using the Cockcroft-Gault Equation\n* Botulinum toxin use within 2 months prior to the Screening Visit\n* Orthopedic surgical procedures in any of the extremities within the past 6 months\n* Diagnosis of multiple sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mathews Adera, MD","affiliation":"Acorda Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Acorda Site #011","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Acorda Site #018","city":"La Jolla","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Acorda Site #016","city":"Newport Beach","state":"California","zip":"92663","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Acorda Site #006","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"Acorda Site #002","city":"Atlantis","state":"Florida","zip":"33462","country":"United States","geoPoint":{"lat":26.5909,"lon":-80.10088}},{"facility":"Acorda Site #015","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Acorda Site #003","city":"Decatur","state":"Georgia","zip":"30033","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"facility":"Acorda Site #021","city":"Lexington","state":"Kentucky","zip":"40513","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Acorda Site #009","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Acorda Site #017","city":"Saginaw","state":"Michigan","zip":"48604","country":"United States","geoPoint":{"lat":43.41947,"lon":-83.95081}},{"facility":"Acorda Site #020","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Acorda Site #023","city":"Reno","state":"Nevada","zip":"89502","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Acorda Site #022","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"Acorda Site #019","city":"Buffalo","state":"New York","zip":"14220","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Acorda Site #007","city":"West Haverstraw","state":"New York","zip":"10993","country":"United States","geoPoint":{"lat":41.20954,"lon":-73.98542}},{"facility":"Acorda Site #004","city":"White Plains","state":"New York","zip":"10605","country":"United States","geoPoint":{"lat":41.03399,"lon":-73.76291}},{"facility":"Acorda Site #013","city":"Charlotte","state":"North Carolina","zip":"28207","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Acorda Site #001","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Acorda Site #008","city":"Norfolk","state":"Virginia","zip":"23507","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Acorda Site #010","city":"Bellevue","state":"Washington","zip":"98004","country":"United States","geoPoint":{"lat":47.61038,"lon":-122.20068}}]},"referencesModule":{"references":[{"pmid":"23652269","type":"DERIVED","citation":"Iaci JF, Parry TJ, Huang Z, Finklestein SP, Ren J, Barrile DK, Davenport MD, Wu R, Blight AR, Caggiano AO. Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion. Stroke. 2013 Jul;44(7):1942-50. doi: 10.1161/STROKEAHA.111.000147. Epub 2013 May 7."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo/Dalfampridine-ER","description":"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:\n\nPeriod 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36\n\ndalfampridine-ER: Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2.\n\n10mg tablets, will be taken orally, twice daily approximately 12 hours apart"},{"id":"FG001","title":"Dalfampridine-ER/Placebo","description":"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:\n\nPeriod 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36\n\ndalfampridine-ER: Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2.\n\n10mg tablets, will be taken orally, twice daily approximately 12 hours apart"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"28"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Non-Compliance -Investigational Drug","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Non-Compliance with Protocol","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Population: The Safety Population consists of all randomized subjects who took at least one dose of investigational product.","groups":[{"id":"BG000","title":"Placebo/Dalfampridine-ER","description":"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:\n\nPeriod 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36\n\ndalfampridine-ER: Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2.\n\n10mg tablets, will be taken orally, twice daily approximately 12 hours apart"},{"id":"BG001","title":"Dalfampridine-ER/Placebo","description":"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:\n\nPeriod 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36\n\ndalfampridine-ER: Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2.\n\n10mg tablets, will be taken orally, twice daily approximately 12 hours apart"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"83"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.5","spread":"9.72"},{"groupId":"BG001","value":"63.5","spread":"8.91"},{"groupId":"BG002","value":"59.5","spread":"9.82"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"28"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"55"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"19"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"60"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs)","description":"A TEAE is defined as any adverse event with date of onset (or worsening) on or after the start-date of double-blind treatment through 7 days after the last dose of double-blind treatment.\n\nThe severity categories of mild, moderate or severe, are defined below:\n\n* Mild is defined as causing no limitation of usual activities\n* Moderate is defined as causing some limitation of usual activities\n* Severe is defined as causing inability to carry out usual activities","populationDescription":"Safety population. Number of participants analyzed is number of patients with TEAE's as described in outcome measure description. Excludes pre-treatment and post-treatment adverse events.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"up to 36 days","groups":[{"id":"OG000","title":"Placebo"},{"id":"OG001","title":"Dalfampridine-ER"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"77"}]}],"classes":[{"title":"Subjects with any TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"42"}]}]},{"title":"TEAEs Possibly Related to study drug","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"24"}]}]},{"title":"TEAEs Maximum Severity - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"29"}]}]},{"title":"TEAEs Maximum Severity - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"}]}]},{"title":"TEAEs Maximum Severity - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"TEAEs leading to withdrawal of study drug","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"TEAEs Serious","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Subjects who died","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Walking Speed Measured by the Timed 25 Foot Walk Test (T25FW)","reportingStatus":"NOT_POSTED","timeFrame":"Screening visit, Days 1, 8, 15, 22, 29 and 36"},{"type":"OTHER_PRE_SPECIFIED","title":"Motor and Sensory Function as Measured by the Fugl-Meyer Assessment (FMA)","reportingStatus":"NOT_POSTED","timeFrame":"Screening visit, Days 1, 8, 15, 22, 29, and 36"},{"type":"OTHER_PRE_SPECIFIED","title":"Manual Dexterity as Measured by the Box and Block Test","reportingStatus":"NOT_POSTED","timeFrame":"Days 1, 8, 15, 22, 29, and 36"},{"type":"OTHER_PRE_SPECIFIED","title":"Assistance Required to Perform Activities of Daily Living (ADL) by the Functional Independence Measure (FIM) Scale","reportingStatus":"NOT_POSTED","timeFrame":"Days 1, 8, 15, 22, 29, and 36"},{"type":"OTHER_PRE_SPECIFIED","title":"Subject Global Impression (SGI) Scale","reportingStatus":"NOT_POSTED","timeFrame":"Days 8, 15, 22, 29 and 36"},{"type":"OTHER_PRE_SPECIFIED","title":"Clinician Global Impression (CGI) Scale","reportingStatus":"NOT_POSTED","timeFrame":"Days 8, 15, 22, 29 and 36"},{"type":"OTHER_PRE_SPECIFIED","title":"Hand Strength as Measured by the Grip Test and Pinch Tests","reportingStatus":"NOT_POSTED","timeFrame":"Days 1, 8, 15, 22, 29, and 36"}]},"adverseEventsModule":{"frequencyThreshold":"1.3","timeFrame":"up to 36 days","description":"All adverse events discussed in this report are treatment-emergent adverse events (TEAEs) unless otherwise indicated. Therefore, events that had a date of onset, or worsening, on or after start of double-blind treatment through 7 days after the last dose of double-blind treatment","eventGroups":[{"id":"EG000","title":"Placebo","seriousNumAffected":2,"seriousNumAtRisk":81,"otherNumAffected":30,"otherNumAtRisk":81},{"id":"EG001","title":"Dalfampridine-ER","seriousNumAffected":2,"seriousNumAtRisk":77,"otherNumAffected":42,"otherNumAtRisk":77}],"seriousEvents":[{"term":"Microcytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Intentional overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]}],"otherEvents":[{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":8,"numAtRisk":77}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":81},{"groupId":"EG001","numAffected":3,"numAtRisk":77}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":81},{"groupId":"EG001","numAffected":4,"numAtRisk":77}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":4,"numAtRisk":77}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":3,"numAtRisk":77}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Drooling","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":77}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":77}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":77}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor (Acorda) has the right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise."},"pointOfContact":{"title":"Study Director","organization":"Acorda Therapeutics, Inc.","phone":"914-347-4300"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000015761","term":"4-Aminopyridine"}],"ancestors":[{"id":"D000026902","term":"Potassium Channel Blockers"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M18011","name":"4-Aminopyridine","asFound":"Carotid Endarterectomy","relevance":"HIGH"},{"id":"M22861","name":"Potassium Channel Blockers","relevance":"LOW"}],"browseBranches":[{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}